NRX-0305: A Pan-Mutant BRAF Degrader with Broad Preclinical Efficacy, Brain Penetrance, and Synergistic Potential with MEK Inhibition Across Class 1/2/3 BRAF-mutant Cancers By webmaster / April 25, 2025
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader For The Treatment Of Primary And Inhibitor-Resistant Solid Tumors By aterrado@waterhousebrands.com / January 7, 2025
NX-1607: A First-In-Class Inhibitor Of Casitas B-Lineage Lymphoma B (CBL-B) For Immuno-Oncology By aterrado@waterhousebrands.com / January 7, 2025
Rational Discovery Of A Small Molecule Intramolecular Glue Inhibitor Of CBL-B That Enhances T-Cell Function By aterrado@waterhousebrands.com / January 7, 2025
First Disclosure Of NX-5948, An Oral Targeted Degrader Of Bruton’s Tyrosine Kinase (BTK) For The Treatment Of B-Cell Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948: BTK Degrader with Activity in Lymphoid Malignancies By aterrado@waterhousebrands.com / January 7, 2025
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study By aterrado@waterhousebrands.com / January 7, 2025
Targeting Degraders To The CNS For The Treatment Of Cancer By dev@sirosolutions.com / December 17, 2024
NX-5948, a Brain-Penetrant BTK Degrader with Clinical Activity in B-cell Malignancies Including CNS Lymphoma By dev@sirosolutions.com / December 17, 2024
